NodThera
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
265 Franklin St Ste 1702, Boston, Massac...Phone Number
(617) 866-7350Website
www.nodthera.comRevenue
$8.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About NodThera
NodThera is a biotechnology company focused on treating chronic diseases by targeting inflammation at its source, specifically through the NLRP3 inflammasome. The company aims to develop innovative medicines that can address various chronic inflammatory diseases, including cardiovascular disease, obesity, and neuroinflammation. Their team consists of experienced biotech innovators dedicated to unlocking the potential of NLRP3-targeting therapies for millions of patients. NodThera's approach is grounded in scientific evidence that positions them as leaders in the field of chronic disease treatment.Explore more
NodThera Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NodThera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when NodThera launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at NodThera
Earning: See what the market has to say on NodThera recently announced quarterly report
Check out if NodThera is spiking on competitors!
NodThera, which may be a good buyer, showed buying intent in Masked Content Topic
Check if NodThera has recently received funding, and reach out quickly before it becomes old news!
Click to see if NodThera had a recent Job posting/layoffs
Funding: Get notified immidiatlly once NodThera has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at NodThera
Find 3 more new buyers
Compare Similar Companies to NodThera
Compare insights from companies similar to NodThera, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NodThera is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NodThera is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NodThera.
NodThera financials insights
Gather financial insights about NodThera, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$40M
2020
Series B
$55M
NodThera Tech Stack
A closer look at the technologies used by NodThera
See more technologies
Most Recent Scoops
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
NodThera News & Media
NodThera Announces Late-Breaking Oral Presentation at the 94th EAS Congress
BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers of cardiometabolic and neurologic diseases, today announced that data from the cardiometabolic Phase 1b clinical trial of its lead candidate, ruvonoflast, previously known as NT-0796, has been accepted for a late-breaking oral presentation at the 94th European Atherosclerosis Society (NodThera to Participate in April Investor Conferences
BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, today announced participation in the following investor conferences:NodThera to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, today announced that Geoff McDonough, M.D., Chief Executive Officer of NodThera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held February 25-26, 2026, in a virtuaNodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer
Dr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical milestones
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NodThera
Sign Up For FreeTo access detailed company insights
NodThera is a biotechnology company focused on treating chronic diseases by targeting inflammation at its source, specifically through the NLRP3 inflammasome. The company aims to develop innovative medicines that can address various chronic inflammatory diseases, including cardiovascular disease, obesity, and neuroinflammation. Their team consists... Read More
